To further evaluate its performance, MGANITE is applied to 256 newly diagnosed acute myeloid leukemia (AML) patients, treated with high dose ara-C (HDAC), Idarubicin (IDA), and HDAC+IDA at M. D. Anderson Cancer Center to estimate ITEs and identify the optimal treatment strategy for each patient. This evidence concerns the gene HDAC9 and acute myeloid leukemia.